Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientifi...( SAN DIEGO June 2 /- Orexigen(R) Thera...)

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009.

ADA: Ernest N. Morial Convention Center, New Orleans, LA.

    Saturday, June 6:  Embargo Lifts June 6 at 9:00 a.m. CT
    Oral Presentation
    Abstract: 37-OR
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, PA
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss:
    A 56-week Phase 3 Study"
    Time: 9:00 a.m. CT
    Location: Room 255

    Monday, June 8:  Embargo Lifts June 6 at 10:00 a.m. CT
    Poster Presentation*
    Abstract: 1731-P
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, Pa.
    Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves
    Quality of Life"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    Poster Presentation*
    Abstract: 1730-P
    Presenter: Samuel Klein, M.D., Washington University School of Medicine,
    St. Louis, Mo.
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss
    Without Worsening Psychiatric Symptoms"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    * Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT
    at a Poster Reception in Hall E

ENDO: Walter E. Washington Convention Center, Washington,
'/>"/>